Related Experiment Video
Updated: Mar 28, 2026
05:31
Author Spotlight: Modeling an Aspect of Preeclampsia in Female Mice Using Hypoxic Human Placenta-Derived Small Extracellular Vesicles
Published on: January 26, 2024
1.5K
Human placenta-derived stromal cells decrease inflammation, placental injury and blood pressure in hypertensive
Piyali Chatterjee1, Valorie L Chiasson1, Lena Pinzur2
1Department of Internal Medicine, Division of Nephrology and Hypertension, Texas A&M Health Science Center/Baylor Scott & White Health, 702 SW HK Dodgen Loop, Temple, TX, U.S.A.
Clinical Science (London, England : 1979)
|December 20, 2015
Summary
Pre-eclampsia treatment using placental expanded (PLX-PAD) cells shows promise. These cells reduced hypertension, proteinuria, and inflammation in a mouse model, offering a potential new therapy for pre-eclampsia.
Area of Science:
- Reproductive Medicine
- Immunology
- Regenerative Medicine
Background:
- Pre-eclampsia is a leading cause of maternal and fetal mortality with no effective treatment besides delivery.
- Maternal immune maladaptation, inflammation, and endothelial dysfunction characterize pre-eclampsia development.
- Extracellular RNA detection by Toll-like receptors (TLRs) 3 and 7 is implicated as a key initiating signal.
Purpose of the Study:
- To investigate the therapeutic potential of placental eXpanded (PLX-PAD) cells in a mouse model of pre-eclampsia.
- To determine if PLX-PAD cells can mitigate inflammation, tissue damage, and hypertension associated with pre-eclampsia.
Main Methods:
- Pre-eclampsia was induced in mice via TLR3 or TLR7 activation.
- PLX-PAD cells were administered on gestational day 14.
- Systolic blood pressure, urinary protein:creatinine ratio, and aortic endothelium-dependent relaxation were measured.
Main Results:
- PLX-PAD cell injection significantly decreased systolic blood pressure and normalized urinary protein:creatinine ratios in TLR3- and TLR7-induced hypertensive mice.
- Endothelium-dependent relaxation responses improved significantly in mice treated with PLX-PAD cells.
- PLX-PAD cells reduced markers of systemic inflammation and placental injury without affecting pregnant control mice or fetuses.
Conclusions:
- PLX-PAD cell therapy safely reversed pre-eclampsia-like features in a mouse model.
- These findings suggest PLX-PAD cells hold therapeutic potential for treating pre-eclampsia.
